AAIC 2026 (Alzheimer's Association International Conference) Opens Sunday July 12 and Runs Through Wednesday July 15 at the ExCeL London — Broader Neurodegeneration Program Beyond Vaccinex Pepinemab SEMA4D Featured Research Session on July 13 Includes AC Immune Three Presentations (First-in-Class TDP-43 PET Tracer With Early Human FTD and ALS Imaging Data, Brain-Penetrant NLRP3 Inhibitor in Phase 1, and Alpha-Synuclein Morphomer With Neuroprotective Preclinical Effects) and Eisai's 50-Plus Alzheimer's Disease Portfolio Presentations Across the Lecanemab Franchise
The Alzheimer's Association International Conference (AAIC 2026) opens Sunday July 12 and runs through Wednesday July 15 at the ExCeL London, drawing approximately 12,000 researchers and health-care professionals from around the globe. The peptide-adjacent centerpiece already flagged in Wednesday's Vaccinex announcement is the Featured Research Session on Monday July 13 for pepinemab (humanized IgG4 anti-Semaphorin 4D monoclonal antibody), chaired by Elizabeth Evans, PhD, presenting new glial biomarker data from the Phase 1b/2 SIGNAL-AD study alongside plans for the expanded Phase 2b SIGNAL-AD2 trial. AC Immune (NASDAQ: ACIU) will present three programs from its Morphomer platform: a first-in-class TDP-43 PET tracer with encouraging early human imaging data in frontotemporal dementia and ALS, a novel brain-penetrant NLRP3 inhibitor in Phase 1 that supports an orally delivered CNS therapy profile, and an alpha-synuclein Morphomer showing potent, brain-penetrant inhibition of pathology with neuroprotective effects. Eisai will present 50-plus abstracts spanning the lecanemab (LEQEMBI) Alzheimer's disease portfolio, including biomarker, long-term safety, and clinical-utility readouts.